MX395521B - Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estas - Google Patents
Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estasInfo
- Publication number
- MX395521B MX395521B MX2018012224A MX2018012224A MX395521B MX 395521 B MX395521 B MX 395521B MX 2018012224 A MX2018012224 A MX 2018012224A MX 2018012224 A MX2018012224 A MX 2018012224A MX 395521 B MX395521 B MX 395521B
- Authority
- MX
- Mexico
- Prior art keywords
- valproic acid
- pharmaceutical formulations
- delayed release
- release pharmaceutical
- pharmaceutically acceptable
- Prior art date
Links
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 title abstract 4
- 229960000604 valproic acid Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000003111 delayed effect Effects 0.000 title 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606197 | 2016-04-08 | ||
| PCT/GB2017/051002 WO2017175013A1 (en) | 2016-04-08 | 2017-04-10 | Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018012224A MX2018012224A (es) | 2019-05-16 |
| MX395521B true MX395521B (es) | 2025-03-25 |
Family
ID=58709491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012224A MX395521B (es) | 2016-04-08 | 2017-04-10 | Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estas |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11395808B2 (OSRAM) |
| EP (1) | EP3439649B1 (OSRAM) |
| JP (1) | JP6985368B2 (OSRAM) |
| KR (1) | KR102438395B1 (OSRAM) |
| CN (2) | CN109414423A (OSRAM) |
| AU (1) | AU2017246697B2 (OSRAM) |
| CA (1) | CA3018043A1 (OSRAM) |
| ES (1) | ES2969021T3 (OSRAM) |
| HU (1) | HUE064701T2 (OSRAM) |
| IL (1) | IL262163B2 (OSRAM) |
| MX (1) | MX395521B (OSRAM) |
| PL (1) | PL3439649T3 (OSRAM) |
| RU (1) | RU2760304C2 (OSRAM) |
| WO (1) | WO2017175013A1 (OSRAM) |
| ZA (1) | ZA201806766B (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| ES2969021T3 (es) | 2016-04-08 | 2024-05-16 | Cereno Scient Ab | Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de las mismas |
| CN113995742B (zh) * | 2021-10-22 | 2023-12-29 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 包含丙戊酸的美白组合物及其用途 |
| GB2613900B (en) * | 2021-12-20 | 2024-01-17 | Cereno Scient Ab | Novel compounds and methods of use thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2026198T3 (es) | 1987-07-22 | 1992-04-16 | Farvalsa Ag | Compuesto a base de acido valproico solido, estable a la humedad y metodo para su preparacion. |
| NZ511900A (en) * | 1999-09-30 | 2003-06-30 | Penwest Pharmaceuticals Co | Sustained release matrix systems for highly soluble drugs |
| AT408718B (de) | 1999-12-02 | 2002-02-25 | Gerot Pharmazeutika | Natriumvalproat-granulat mit verringerter hygroskopizität |
| WO2002055017A2 (en) | 2000-11-21 | 2002-07-18 | Wake Forest University | Method of treating autoimmune diseases |
| US6610326B2 (en) * | 2001-02-16 | 2003-08-26 | Andrx Corporation | Divalproex sodium tablets |
| ITMI20011733A1 (it) | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc |
| US20040043026A1 (en) | 2002-05-13 | 2004-03-04 | Tai-Lan Tuan | Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| US20040224006A1 (en) | 2003-04-21 | 2004-11-11 | Samn Raffaniello | Ancrod irradiated, impregnated or coated sutures and other first aid or wound management bandaging materials for minimizing scarring and/or preventing excessive scar formation |
| ITMI20040876A1 (it) | 2004-04-30 | 2004-07-30 | Univ Degli Studi Milano | Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari |
| US7713550B2 (en) * | 2004-06-15 | 2010-05-11 | Andrx Corporation | Controlled release sodium valproate formulation |
| US20050276848A1 (en) * | 2004-06-15 | 2005-12-15 | Nilobon Podhipleux | Sustained release neutralized divalproex sodium |
| WO2006117165A2 (en) | 2005-05-02 | 2006-11-09 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Means and methods for the treatment of head injuries and stroke |
| EP1743654A1 (en) | 2005-07-15 | 2007-01-17 | TopoTarget Germany AG | Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases |
| AU2006287378A1 (en) | 2005-09-07 | 2007-03-15 | Braincells, Inc. | Modulation of neurogenesis by HDac inhibition |
| WO2007030080A1 (en) | 2005-09-08 | 2007-03-15 | S*Bio Pte Ltd | Heterocyclic compounds |
| US20070082046A1 (en) * | 2005-10-11 | 2007-04-12 | Banner Pharmacaps, Inc. | Enteric valproic acid |
| EP1815850B1 (en) * | 2006-01-11 | 2008-11-26 | Teva Pharmaceutical Industries Ltd. | Controlled release formulation of divalproic acid and its derivatives |
| WO2007084775A2 (en) | 2006-01-20 | 2007-07-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for modulation of suppressor t cell activation |
| AU2007234380A1 (en) | 2006-04-06 | 2007-10-11 | Novartis Ag | Combination of organic compounds |
| BRPI0716196A2 (pt) * | 2006-08-31 | 2013-11-12 | Eurand Inc | Sistemas de distribuição de fármacos que compreendem soluções sólidas de fármacos fracamente básicos. |
| WO2008154402A2 (en) | 2007-06-06 | 2008-12-18 | University Of Maryland, Baltimore | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
| WO2009009737A1 (en) * | 2007-07-12 | 2009-01-15 | Neurosci, Inc. | Sustained release formulation of active pharmaceuticals in a lipid based sustained release |
| US20090270497A1 (en) | 2008-04-24 | 2009-10-29 | Pharmacyclics, Inc. | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors |
| GB201003766D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Pulsatile drug release |
| US20110245154A1 (en) | 2010-03-11 | 2011-10-06 | Hemaquest Pharmaceuticals, Inc. | Methods and Compositions for Treating Viral or Virally-Induced Conditions |
| CN101947209B (zh) * | 2010-07-21 | 2012-07-25 | 河南中帅医药科技发展有限公司 | 双丙戊酸钠小丸及其制备方法 |
| PL2683371T3 (pl) * | 2011-03-09 | 2021-04-19 | Cereno Scientific Ab | Związki i sposoby poprawy zaburzonej funkcji wewnątrzustrojowej fibrynolizy przy zastosowaniu inhibitorów deacetylazy histonowej |
| KR101892788B1 (ko) | 2011-09-13 | 2018-08-28 | 파마싸이클릭스 엘엘씨 | 벤다무스틴과 조합된 히스톤 디아세틸라제 억제제의 제제 및 그의 용도 |
| CN104248627A (zh) * | 2013-06-25 | 2014-12-31 | 北大方正集团有限公司 | 丙戊酸半钠泡腾干混悬剂及其制备方法 |
| GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| WO2017175010A1 (en) | 2016-04-08 | 2017-10-12 | Cereno Scientific Ab | Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation |
| ES2969021T3 (es) | 2016-04-08 | 2024-05-16 | Cereno Scient Ab | Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de las mismas |
-
2017
- 2017-04-10 ES ES17723734T patent/ES2969021T3/es active Active
- 2017-04-10 US US16/090,664 patent/US11395808B2/en active Active
- 2017-04-10 EP EP17723734.4A patent/EP3439649B1/en active Active
- 2017-04-10 CA CA3018043A patent/CA3018043A1/en active Pending
- 2017-04-10 MX MX2018012224A patent/MX395521B/es unknown
- 2017-04-10 JP JP2019503794A patent/JP6985368B2/ja active Active
- 2017-04-10 WO PCT/GB2017/051002 patent/WO2017175013A1/en not_active Ceased
- 2017-04-10 CN CN201780025746.XA patent/CN109414423A/zh active Pending
- 2017-04-10 HU HUE17723734A patent/HUE064701T2/hu unknown
- 2017-04-10 RU RU2018137399A patent/RU2760304C2/ru active
- 2017-04-10 KR KR1020187031904A patent/KR102438395B1/ko active Active
- 2017-04-10 AU AU2017246697A patent/AU2017246697B2/en active Active
- 2017-04-10 CN CN202111575415.8A patent/CN114209667A/zh active Pending
- 2017-04-10 PL PL17723734.4T patent/PL3439649T3/pl unknown
-
2018
- 2018-10-07 IL IL262163A patent/IL262163B2/en unknown
- 2018-10-11 ZA ZA2018/06766A patent/ZA201806766B/en unknown
-
2022
- 2022-07-19 US US17/868,323 patent/US12023311B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL262163A (en) | 2018-11-29 |
| KR20180127480A (ko) | 2018-11-28 |
| US20190111011A1 (en) | 2019-04-18 |
| JP2019510834A (ja) | 2019-04-18 |
| ZA201806766B (en) | 2024-03-27 |
| ES2969021T3 (es) | 2024-05-16 |
| PL3439649T3 (pl) | 2024-03-18 |
| US12023311B2 (en) | 2024-07-02 |
| RU2760304C2 (ru) | 2021-11-23 |
| US11395808B2 (en) | 2022-07-26 |
| EP3439649A1 (en) | 2019-02-13 |
| CN114209667A (zh) | 2022-03-22 |
| JP6985368B2 (ja) | 2021-12-22 |
| IL262163B1 (en) | 2023-03-01 |
| HUE064701T2 (hu) | 2024-04-28 |
| EP3439649B1 (en) | 2023-11-15 |
| AU2017246697B2 (en) | 2022-06-02 |
| CN109414423A (zh) | 2019-03-01 |
| CA3018043A1 (en) | 2017-10-12 |
| NZ746269A (en) | 2024-10-25 |
| RU2018137399A3 (OSRAM) | 2020-06-18 |
| WO2017175013A1 (en) | 2017-10-12 |
| KR102438395B1 (ko) | 2022-08-30 |
| US20230120670A1 (en) | 2023-04-20 |
| IL262163B2 (en) | 2023-07-01 |
| MX2018012224A (es) | 2019-05-16 |
| AU2017246697A1 (en) | 2018-10-04 |
| RU2018137399A (ru) | 2020-05-12 |
| BR112018070626A2 (pt) | 2019-02-05 |
| EP3439649C0 (en) | 2023-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
| WO2016105564A8 (en) | Quinazoline derivatives used to treat hiv | |
| NZ733135A (en) | Fused pyrimidine compounds for the treatment of hiv | |
| WO2017037594A3 (zh) | 用于减少局部脂肪的医药组成物及其用途 | |
| WO2018165404A8 (en) | Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol | |
| MY187358A (en) | Modified release orally administered amino acid formulations | |
| PH12017502376A1 (en) | Oral solid formulation containing irinotecan and method of preparing the same | |
| PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
| MX395521B (es) | Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estas | |
| CL2017001840A1 (es) | Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para preparar y usar las mismas. | |
| EP4257149A3 (en) | Stable liquid gonadotropin formulation | |
| GEP20237486B (en) | Formulations of copanlisib | |
| WO2019240699A3 (en) | Tablet formulations comprising metformin and sitagliptin processed with hot-melt extrusion | |
| GEP20196977B (en) | Pharmaceutical formulations of vildagliptin | |
| AU2017277002A1 (en) | Pharmaceutically acceptable salt as renal outer medullary potassium channel inhibitor | |
| WO2016197042A8 (en) | Modified or targeted release formulations of linaclotide | |
| WO2019209217A3 (en) | Modified release formulations of flurbiprofen | |
| MX2021016053A (es) | Formulaciones de espuma rectal. | |
| MX2019005005A (es) | Tableta de liberacion extendida que comprende un farmaco de perdida de peso. | |
| TN2016000561A1 (en) | Stabilized desmopressin | |
| EA202090803A1 (ru) | Фармацевтическая композиция адапалена и миноциклина для наружного применения | |
| WO2019125166A3 (en) | Hyaluronic acid formulations | |
| UA91650U (uk) | Фармацевтична композиція похідних гамма-аміномасляної кислоти для твердих капсул | |
| GB2541348A (en) | Clopidogrel for use in the treatment of benign prostatic hyperplasia |